Melodia to spend up to $275M on Alivexis' cathepsin C inhibitor

Melodia Therapeutics announced on Friday that it has secured an exclusive, global license for Alivexis' cathepsin C inhibitor, MDI-0151. The Swiss biotechnology company aims to advance this candidate, which it believes holds best-in-class potential, into Phase I/IIa clinical trials for treating refractory inflammatory diseases driven by excessive neutrophil activation, including ANCA-associated vasculitis.

Cathepsin C is an enzyme that activates specific proteases, which can lead to tissue damage associated with neutrophils. According to Alivexis, MDI-0151 is designed to manage immune and inflammatory conditions without impairing the immune function of neutrophils. The agreement specifies that Alivexis will receive up to $275 million through an initial payment and additional development and sales milestones. Additionally, the company will earn royalties on the net sales of any approved product. Alivexis may also obtain warrants for shares of Melodia’s common stock.

In summary, Melodia Therapeutics' acquisition of the worldwide license for MDI-0151 from Alivexis marks a significant step toward developing new treatments for severe inflammatory diseases by focusing on neutrophil activation pathways. The collaboration includes substantial financial terms and potential equity stakes, underscoring the high hopes pinned on this promising therapeutic candidate.